-
EP4038194
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4038194
| EP4038194 - METHODS FOR IMPROVED THERAPEUTIC USE OF RECOMBINANT AAV [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 08.07.2022 Database last updated on 24.08.2024 | |
| Former | The international publication has been made Status updated on 10.04.2021 | ||
| Former | unknown Status updated on 03.11.2020 | Most recent event Tooltip | 24.04.2024 | Change - representative | Applicant(s) | For all designated states Ultragenyx Pharmaceutical Inc. 60 Leveroni Court Novato, CA 94949 / US | [2022/32] | Inventor(s) | 01 /
SULLIVAN, Barbara, Anne 55 Pamela Ct. Tiburon, CA 94920 / US | 02 /
MCKEEVER, Kathleen, Phillips 51 Foothill Road San Anselmo, CA 94960 / US | [2022/32] | Representative(s) | Haseltine Lake Kempner LLP Cheapside House 138 Cheapside London EC2V 6BJ / GB | [N/P] |
| Former [2022/32] | AWA Sweden AB Box 45086 104 30 Stockholm / SE | Application number, filing date | 20796975.9 | 01.10.2020 | [2022/32] | WO2020US53805 | Priority number, date | US201962910790P | 04.10.2019 Original published format: US 201962910790 P | [2022/32] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021067598 | Date: | 08.04.2021 | Language: | EN | [2021/14] | Type: | A1 Application with search report | No.: | EP4038194 | Date: | 10.08.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 08.04.2021 takes the place of the publication of the European patent application. | [2022/32] | Search report(s) | International search report - published on: | EP | 08.04.2021 | Classification | IPC: | C12N15/86, A61K39/00, A61K31/573 | [2022/32] | CPC: |
C12N15/86 (EP);
A61K39/3955 (US);
A61K31/5377 (US);
A61K31/573 (EP,US);
A61K31/675 (US);
A61K31/69 (US);
A61K38/1825 (US);
A61K38/36 (US);
A61K38/37 (US);
A61K38/44 (US);
A61K38/45 (US);
A61K38/46 (US);
A61K38/465 (US);
A61K38/48 (US);
A61K38/4873 (US);
A61K38/53 (US);
A61K45/06 (EP);
A61K48/0083 (US);
| C-Set: |
A61K31/573, A61K2300/00 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/32] | Title | German: | VERFAHREN ZUR VERBESSERTEN THERAPEUTISCHEN VERWENDUNG VON REKOMBINANTEM AAV | [2022/32] | English: | METHODS FOR IMPROVED THERAPEUTIC USE OF RECOMBINANT AAV | [2022/32] | French: | PROCÉDÉS POUR UNE UTILISATION THÉRAPEUTIQUE AMÉLIORÉE D'AAV RECOMBINANT | [2022/32] | Entry into regional phase | 21.04.2022 | National basic fee paid | 21.04.2022 | Designation fee(s) paid | 21.04.2022 | Examination fee paid | Examination procedure | 21.04.2022 | Examination requested [2022/32] | 21.04.2022 | Date on which the examining division has become responsible | 22.11.2022 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 20.01.2023 | Renewal fee patent year 03 | 06.10.2023 | Renewal fee patent year 04 | Penalty fee | Additional fee for renewal fee | 31.10.2022 | 03 M06 Fee paid on 20.01.2023 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]WO2011097456 (UNIV NORTH CAROLINA [US], et al) [Y] 30-32 * example -; claim - *; | [Y]WO2011139379 (UNIV DUKE [US], et al) [Y] 1-68 * page 7, paragraph 3 - page 8, paragraph 1; page 10, paragraph 3 - page 24; page 27, paragraph 2 - page 29, paragraph 4; claims *; | [Y]WO2015164758 (UNIV FLORIDA [US]) [Y] 1-68 * example -; claim - *; | [YDP]WO2020016318 (INST NAT SANTE RECH MED [FR], et al) [YDP] 1* example -; claim - *; | [Y] - CORTI M ET AL, "B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study", MOLECULAR THERAPY - METHODS & CLINICAL DEVELOPMENT, (20140813), vol. 1, doi:10.1038/mtm.2014.33, page 14033, XP055233218 [Y] 1-68 * abstract, results, discussion, figure 1; * DOI: http://dx.doi.org/10.1038/mtm.2014.33 | [Y] - CHEN D ET AL, "Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies", JOURNAL OF CLINICAL MEDICINE, (20161124), vol. 5, no. 12, doi:10.3390/jcm5120107, page 107, XP055764293 [Y] 1-68 * abstract, items 3 and 5, conclusions; * DOI: http://dx.doi.org/10.3390/jcm5120107 | [Y] - FORSTHUBER T G ET AL, "B cell -based therapies in CNS autoimmunity: differentiating CD 19 and CD 20 as therapeutic targets", THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, (20180321), vol. 11, doi:10.1177/1756286418761697, pages 1 - 13, XP055735771 [Y] 1-68 * abstract, page 3, left-hand column, paragraph 3 - page 6, left-hand column, paragraph 2; * DOI: http://dx.doi.org/10.1177/1756286418761697 | [Y] - Collin M et al, "Toward Clinical use of the IgG Specific Enzymes IdeS and EndoS against Antibody-Mediated Diseases", Collin M et al, COLLIN M ET AL, Bacterial Pathogenesis: Methods and Protocols, Methods in Molecular Biology, SPRINGER SCIENCE - BUSINESS MEDIA, NEW YORK, NY, US,, (20170101), vol. 1535, pages 339 - 351, doi:10.1007/978-1-4939-6676-8_23, ISSN 1940-6029, ISBN 978-1-4939-1965-9, XP009512218 [Y] 33,34 * abstract, item 4; * DOI: http://dx.doi.org/10.1007/978-1-4939-6673-8_23 | by applicant | EP1310571 | WO03042397 | WO2005012493 | WO2005033321 | WO2006089133 | WO2007002223 | US2007036760 | WO2007076950 | WO2007082715 | US7282199 | WO2008022152 | WO2008031056 | WO2009052431 | WO2009054863 | US2009197338 | WO2010053716 | WO2010095031 | US7790449 | WO2010102276 | US7906111 | WO2011147834 | WO2012010561 | WO2012057765 | US2012219528 | US8323653 | US8524867 | US8734809 | US8883992 | US8927514 | WO2015074085 | US2015344911 | WO2016033570 | WO2016049230 | WO2016081029 | US9506083 | US2017021114 | WO2017015783 | US9585971 | US9587282 | US9611302 | WO2017055328 | WO2017066136 | WO2017117530 | US9725485 | WO2017134274 | WO2017165859 | US9803020 | US9856539 | WO2018002031 | US2018023070 | WO2018022905 | US2018037962 | US9896505 | US9909142 | US9920097 | WO2018108106 | WO2018118102 | WO2018119163 | US10011640 | WO2018126369 | WO2018156654 | US10081659 | WO2018222503 | WO2018222926 | WO2018226602 | US10179176 | US10202657 | US10214566 | US10214785 | WO2019057100 | US10266845 | US10294281 | US10301648 | US10385320 | US10392632 | WO2019168961 | WO2019191780 | WO2020016318 | WO2020118239 | WO2020154746 | WO2020159970 | - CORTI et al., Mol Ther Methods Clin Dev, (20140000), vol. 1, page 14033 | - BESSIS et al., Gene Therapy, (20040000), vol. 11, pages S10 - S17 | - AMANNA et al., NEJM, (20070000), vol. 357, no. 19, pages 1903 - 15 | - CROTTY et al., The Journal of Immunology, (20030000), vol. 171, pages 4969 - 4973 | - BHOJ et al., Blood, (20160000), vol. 12, pages 360 - 370 | - OWCZARCZYK et al., Science Translational Medicine, (20110000), vol. 3, page 101ra92 | - MEI et al., Blood, (20150000), vol. 125, pages 1739 - 1748 | - BRYNJOLFSSON et al., Blood Adv, (20170000), vol. 1, pages 835 - 838 | - LAMPHIER et al., Mol Pharmacol., (20140000), vol. 85, no. 3, pages 429 - 40 | - CHOI et al., Curr Gene Ther, (20050000), vol. 5, pages 285 - 297 |